DHR · CIK 313616
What Danaher Corporation told the SEC could break it.
Danaher's disclosures center on its international footprint and, within it, China. About 59% of its 2025 sales came from outside the U.S. — roughly 11% ($2.6B) from China — and many of its manufacturing operations and suppliers sit abroad too, concentrating both currency and geopolitical exposure. That footprint is squarely in the path of trade friction: new U.S. tariffs, retaliatory measures, and Chinese export restrictions on certain manufacturing components, with added uncertainty after a February 2026 Supreme Court ruling on IEEPA-based tariffs. China is also a pricing pressure point, where its volume-based procurement program and healthcare-reimbursement changes cut segment prices about 1.0% in 2025. Separately, for certain spec- or qualification-restricted components, only a single or limited number of suppliers can readily provide them.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs (China export restrictions on components) and Feb 2026 Supreme Court IEEPA rulingmedium
New U.S. tariffs on imports from many countries prompted retaliatory tariffs and Chinese export restrictions on certain manufacturing components; additional sector tariffs are threatened, and in February 2026 the U.S. Supreme Court ruled on IEEPA-based tariffs — creating ongoing trade-cost and supply-availability uncertainty.
“including tariffs and export restrictions on certain manufacturing components imposed by China and tariffs pursuant to trade agreements the U.S. has entered into with certain countries. In addition, a number of new tariffs have been threatened by the U.S. and other countries, including tariffs in certain industry sectors.”
- China volume-based procurement (VBP) and healthcare-reimbursement price cutsmedium
China's volume-based procurement program and healthcare-reimbursement changes drove segment price decreases of ~1.0% in 2025, with China and other countries/private payors controlling healthcare-product prices via reimbursement, pricing or coverage limits.
“Price decreases in the segment of 1.0%, primarily attributable to the volume-based procurement program and healthcare reimbursement changes in China and to a lesser extent, sales promotions, negatively impacted the year-over-year change in sales during 2025”
Geographic concentration
- ~59% of sales outside U.S.; China ~11% of sales with offshore manufacturing/suppliersmedium
About 59% of Danaher's 2025 continuing-operations sales were from customers outside the U.S., with ~11% from China ($2.6B of $24.6B); many manufacturing operations, suppliers and employees are also outside the U.S., concentrating geopolitical and FX exposure.
“In 2025 approximately 59% of our sales from continuing operations were derived from customers outside the U.S. In addition, many of our manufacturing operations, suppliers and employees are located outside the U.S.”
Sole-source dependency
- single/limited-source suppliers for spec- or qualification-restricted componentsmedium
Danaher buys raw materials from many sources (no single supplier is material), but for some components requiring particular specifications or regulatory/other qualifications, only a single supplier or a limited number can readily provide them.
“For some components that require particular specifications or regulatory or other qualifications only a single supplier or a limited number of suppliers can readily provide such components.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch